Aerosolized medications are increasingly being used in ventilator-dependent patients. There are many issues with selection and use of aerosol delivery devices in patients receiving ventilator support. The purpose of this paper is to explain potential problems associated with aerosol devices, delivery technique, and clinical response to therapy to assure patient well-being and safety during inhalation therapy.
Division of Respiratory Therapy, College of Health and Human Sciences, Georgia State University, Atlanta, GA
The study was conducted in the Aerosol Research Lab at Georgia State University.
Disclosure: J.B.F. serves as a consultant to the biotech industry. His clients include Aerogen, Ansun, Aridis, Bayer, Dance Biopharm, Parion, Quark, and WHO. He currently serves as Chief Clinical Officer for Aerogen, and Senior Fellow, Aerosol Device Development for Dance Biopharm. He is an adjunct Professor to the Respiratory Care Programs at Georgia State in Atlanta, and Rush Medical School in Chicago. In addition, he has a grant from the Brazilian government to serve as a Scholar without Borders working with the Cardiopulmonary Physiotherapy Department at Federale University of Pernumbuco in Recife, Brazil. In all 3 academic programs he supervises graduate students in Aerosol Research. He has involvement with the following products: Aeroneb Pro, Solo, Go and Lab (Aerogen), PPDS system for Amikacin (Bayer), Dance 501 Inhaler for insulin (Dance Biopharm), Prototype nasal delivery system (Parion), and Measles vaccine delivery system for mass campaigns in third world (WHO). A.A. declares that there are no conflicts of interest.
Address correspondence to: Arzu Ari, PhD, RRT, PT, CPFT, FAARC, Division of Respiratory Therapy, College of Health and Human Sciences, Georgia State University, P.O. Box 4019, Atlanta, GA 30302-4019. E-mail: email@example.com.